Search Results
Mar 31, 2026, 20:49 ET The $578 Billion Regenerative Medicine Market Has a Manufacturing Problem. One Company Just Solved the First Step
demonstrating that manufactured biologics can deliver sustained, measurable reversal of chronic organ damage.Iovance Biotherapeutics (NASDAQ: IOVA) received FDA approval for Amtagvi, a tumor-infiltrating lymphocyte therapy for advanced melanoma — the first approved TIL therapy, which requires extracting
More news about: USA News Group
Mar 24, 2026, 10:00 ET Advanced Cell-based Therapy Booming the Success for Healthcare Sector
demonstrating that biological interventions can deliver sustained, measurable reversal of chronic organ damage.Iovance Biotherapeutics (NASDAQ: IOVA) received FDA approval for Amtagvi, the first approved tumor-infiltrating lymphocyte therapy for advanced melanoma. It's a landmark, but each treatment
More news about: USA News Group
Mar 05, 2026, 09:00 ET Next-Generation Cancer Therapies Post Breakthrough Results Across Multiple Tumor Types
multiple tumor types include Oncolytics Biotech (NASDAQ: ONCY), Vir Biotechnology (NASDAQ: VIR), Iovance Biotherapeutics (NASDAQ: IOVA), C4 Therapeutics (NASDAQ: CCCC), and Immunocore (NASDAQ: IMCR).
More news about: Equity Insider
Oct 29, 2025, 08:30 ET Nanomedicine Innovations Transforming Oncology Drug Delivery and Bioavailability
as an innovator along with other companies working to make a difference in cancer treatment, including Iovance Biotherapeutics Inc. (NASDAQ: IOVA), Merck & Co. Inc. (NYSE: MRK), Eli Lilly and Company (NYSE: LLY) and Johnson & Johnson (NYSE: JNJ)
More news about: NetworkNewsWire
Oct 15, 2025, 08:45 ET Cellular Immunotherapy Breakthroughs Fuel $370 Billion Market Surge
Therapeutics, Inc. (NASDAQ: PSTV), Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), and I-Mab (NASDAQ: IMAB).
More news about: Equity Insider
Sep 17, 2025, 08:30 ET Advancing Cancer Research Brings New Hope for Patients Worldwide
cancer and rare diseases are treated. In doing so, it positions itself among the innovators — including Iovance Biotherapeutics Inc. (NASDAQ: IOVA), Merck & Co. Inc. (NYSE: MRK), AstraZeneca PLC (NASDAQ: AZN) and Bristol-Myers Squibb Co. (NYSE: BMY) — that are driving advances
More news about: NetworkNewsWire
Aug 14, 2025, 12:22 ET Cancer Treatment Stocks Surge as $866B Market Attracts Private Investment
and clear regulatory strategies, including Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), Fate Therapeutics, Inc. (NASDAQ: FATE), Inovio Pharmaceuticals, Inc. (NASDAQ: INO), and Nektar Therapeutics (NASDAQ: NKTR).
More news about: USA News Group
Jul 14, 2025, 09:04 ET IOVA Shareholders Have the Right to Lead the Iovance Biotherapeutics, Inc. Securities Lawsuit - Contact the DJS Law Group to Discuss Your Rights - ELV
The DJS Law Group reminds investors of a class action lawsuit against Iovance Biotherapeutics, Inc. ("Iovance" or "the Company") (NASDAQ: IOVA) for violations of the federal securities laws. Shareholders who purchased the Company's securities between May 9, 2024
More news about: DJS Law Group LLP
Jul 14, 2025, 09:00 ET Lost Money on Iovance Biotherapeutics, Inc.(IOVA)? Join Class Action Suit Seeking Recovery - Contact The Gross Law Firm
14, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Iovance Biotherapeutics, Inc. (NASDAQ: IOVA).
More news about: The Gross Law Firm
Jul 14, 2025, 03:48 ET IOVA Investors Have Opportunity to Lead Iovance Biotherapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
IOVA) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by
More news about: The Schall Law Firm
Jul 13, 2025, 15:26 ET IOVA Deadline: IOVA Investors with Losses in Excess of $100K Have Opportunity to Lead Iovance Biotherapeutics, Inc. Securities Fraud Lawsuit
2025 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) securities between May 9, 2024 and May 8, 2025, both dates inclusive (the "Class Period"),
More news about: THE ROSEN LAW FIRM, P. A.
Jul 12, 2025, 10:00 ET INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Iovance Biotherapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - IOVA
/PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Iovance Biotherapeutics, Inc. ("Iovance" or the "Company") (NASDAQ: IOVA). Such investors are advised to contact Danielle Peyton at [email protected] or
More news about: Pomerantz LLP
Jul 11, 2025, 13:12 ET Iovance Biotherapeutics, Inc. (IOVA) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
IOVA) have opportunity to lead the securities fraud class action lawsuit.
More news about: The Law Offices of Frank R. Cruz, Los Angeles
Jul 11, 2025, 09:00 ET July 14, 2025 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against IOVA
2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Iovance Biotherapeutics, Inc. ("Iovance" or the "Company") (NASDAQ: IOVA) of a class action securities lawsuit.
More news about: Levi & Korsinsky, LLP
Jul 10, 2025, 12:00 ET Iovance Biotherapeutics, Inc. (IOVA) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
IOVA).
More news about: Glancy Prongay & Murray LLP
Jul 10, 2025, 09:00 ET The Gross Law Firm Announces the Filing of a Securities Class Action on Behalf of Iovance Biotherapeutics, Inc.(IOVA) Shareholders
10, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Iovance Biotherapeutics, Inc. (NASDAQ: IOVA).
More news about: The Gross Law Firm
Jul 08, 2025, 12:00 ET Iovance Biotherapeutics, Inc. (IOVA) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
IOVA). IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN IOVANCE BIOTHERAPEUTICS, INC. (IOVA), CONTACT THE LAW OFFICES OF HOWARD G. SMITH BEFORE JULY 14, 2025
More news about: Law Offices of Howard G. Smith
Jul 08, 2025, 10:45 ET IOVA Investors Have the Opportunity to Lead the Iovance Biotherapeutics Securities Fraud Lawsuit with Faruqi & Faruqi, LLP
leading national securities law firm, is investigating potential claims against Iovance Biotherapeutics, Inc. ("Iovance" or the "Company") (NASDAQ: IOVA) and reminds investors of the July 14, 2025 deadline to seek the role of lead plaintiff in a federal securities
More news about: Faruqi & Faruqi, LLP
Jul 08, 2025, 09:00 ET Levi & Korsinsky Notifies Shareholders of Iovance Biotherapeutics, Inc.(IOVA) of a Class Action Lawsuit and an Upcoming Deadline
2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Iovance Biotherapeutics, Inc. ("Iovance" or the "Company") (NASDAQ: IOVA) of a class action securities lawsuit.
More news about: Levi & Korsinsky, LLP
Jul 07, 2025, 20:30 ET IOVA Deadline: IOVA Investors Have Opportunity to Lead Iovance Biotherapeutics, Inc. Securities Fraud Lawsuit
2025 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) securities between May 9, 2024 and May 8, 2025, both dates inclusive (the "Class Period"),
More news about: THE ROSEN LAW FIRM, P. A.
Jul 07, 2025, 14:45 ET INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Iovance Biotherapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - IOVA
/PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Iovance Biotherapeutics, Inc. ("Iovance" or the "Company") (NASDAQ: IOVA). Such investors are advised to contact Danielle Peyton at [email protected] or
More news about: Pomerantz LLP
Jul 07, 2025, 12:00 ET Iovance Biotherapeutics, Inc. (IOVA) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
IOVA) have opportunity to lead the securities fraud class action lawsuit.
More news about: The Law Offices of Frank R. Cruz, Los Angeles
Jul 07, 2025, 10:04 ET IOVA Shareholders Have the Right to Lead the Iovance Biotherapeutics, Inc. Securities Lawsuit - Contact the DJS Law Group to Discuss Your Rights - ELV
The DJS Law Group reminds investors of a class action lawsuit against Iovance Biotherapeutics, Inc. ("Iovance" or "the Company") (NASDAQ: IOVA) for violations of the federal securities laws.
More news about: DJS Law Group LLP
Jul 07, 2025, 10:03 ET IOVA Investors Have Opportunity to Lead Iovance Biotherapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
IOVA) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by
More news about: The Schall Law Firm
Jul 07, 2025, 09:00 ET IOVA LAWSUIT ALERT: The Gross Law Firm Notifies Iovance Biotherapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
7, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Iovance Biotherapeutics, Inc. (NASDAQ: IOVA).
More news about: The Gross Law Firm